Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib

Trial Profile

Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Veliparib (Primary) ; Temozolomide
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 04 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
    • 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top